Study: Drug sensitises to radiation, reduces spread of prostate cancer : upi

referring to upi

Study: Drug sensitises to radiation, reduces spread of prostate cancer

Study: Drug sensitises to radiation, reduces spread of prostate cancer

BALTIMORE, Nov. 9 (UPI) -- Research conducted by Johns Hopkins Medicine suggests an experimental drug targeting abnormally high levels of a protein linked to cancer growth, specifically RNA helicase DDX3, seems to reduce the spread of prostate cancer cells, while also making the cells more vulnerable to radiation.In the study, published in the American Association for Cancer Research, researchers found that by specifically targeting and blocking DDX3 -- which is seen in high levels in men with prostate cancer -- the survival and proliferation of cancerous cells is "significantly reduced."For the study, researchers designed a small molecule, identified as RK-33, that would dock into DDX3's ATP-binding domain, which "perturbed" DDX3's activity.When the prostate cancer cell lines of DU145, 22Rv1, and LNCaP, which all have high levels of DDX3, were treated, RK-33 was able to decrease the proliferation of cancerous cells, while also inducing a G1 phase cell cycle arrest -- meaning a cell did not move past the first of the four phases of the cell cycle.


as well dailymail

Simple jab that could treat deadliest type of prostate cancer

Simple jab that could treat deadliest type of prostate cancer

A jab for the deadliest types of prostate cancer is being developed by British scientists.Men are currently treated with chemotherapy or radiotherapy, which causes debilitating side effects.But researchers from University College London say they are close to developing a new injection.Scroll down for videoMen are currently treated with chemotherapy or radiotherapy, which causes debilitating side effectsThis would target the cancerous cells but spare the healthy cells nearby – thereby causing far fewer side effects.


additionally foxnews

Second opinions not likely to change prostate cancer treatment

Second opinions not likely to change prostate cancer treatment

Though many men diagnosed with prostate cancer seek a second opinion before beginning treatment, second opinions are unlikely to change their treatment decisions, according to a U.S. study.Prostate cancer management options range from surgery and radiation to "watchful waiting."Most men with prostate cancer are over age 65 and do not die from the disease, so treatment may not improve health or lengthen life in all cases, according to the Centers for Disease Control and Prevention."We were surprised by the relatively large percentage of men who obtain second opinions for their prostate cancer," said lead author Dr. Archana Radhakrishnan of Johns Hopkins University in Baltimore.